MCID: TTN003
MIFTS: 65

Tetanus

Categories: Rare diseases, Neuronal diseases, Infectious diseases

Aliases & Classifications for Tetanus

MalaCards integrated aliases for Tetanus:

Name: Tetanus 12 72 49 55 51 40 3 3 41 14 69
Lockjaw 49 3
Infection Due to Clostridium Tetani 12
Clostridial Tetanus 12

Characteristics:

Orphanet epidemiological data:

55
tetanus
Prevalence: <1/1000000 (France),<1/1000000 (Europe);

Classifications:



External Ids:

Disease Ontology 12 DOID:11338
ICD10 32 A35
ICD9CM 34 037
MeSH 41 D013742
NCIt 46 C85185
Orphanet 55 ORPHA3299
MESH via Orphanet 42 D013742
UMLS via Orphanet 70 C0039614
ICD10 via Orphanet 33 A33 A34 A35
UMLS 69 C0039614

Summaries for Tetanus

MedlinePlus : 40 Tetanus is a serious illness caused by Clostridium bacteria. The bacteria live in soil, saliva, dust, and manure. The bacteria can enter the body through a deep cut, like those you might get from stepping on a nail, or through a burn. The infection causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw. This makes it impossible to open your mouth or swallow. Tetanus is a medical emergency. You need to get treatment in a hospital. A vaccine can prevent tetanus. It is given as a part of routine childhood immunization. Adults should get a tetanus shot, or booster, every 10 years. If you get a bad cut or burn, see your doctor - you may need a booster. Immediate and proper wound care can prevent tetanus infection.

MalaCards based summary : Tetanus, also known as lockjaw, is related to diphtheria and poliomyelitis, and has symptoms including pruritus and fever. An important gene associated with Tetanus is VAMP7 (Vesicle Associated Membrane Protein 7), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Iron and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

CDC : 3 Tetanus is an infection caused by bacteria called Clostridium tetani. When the bacteria invade the body, they produce a poison (toxin) that causes painful muscle contractions. Another name for tetanus is “lockjaw”. It often causes a person’s neck and jaw muscles to lock, making it hard to open the mouth or swallow. CDC recommends vaccines for infants, children, teens, and adults to prevent tetanus.

Disease Ontology : 12 A primary bacterial infectious disease that results_in prolonged contraction of skeletal muscle fibers, has material basis in Clostridium tetani, which produces tetanospasmin, a neurotoxin, which is carried to the brain and spinal cord, where it binds irreversibly to receptors inhibiting neurotransmission. Damaged upper motor neurons cannot control reflex responses to afferent sensory stimuli.

Wikipedia : 72 Tetanus, also known as lockjaw, is an infection characterized by muscle spasms. In the most common type,... more...

Related Diseases for Tetanus

Diseases related to Tetanus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 370)
# Related Disease Score Top Affiliating Genes
1 diphtheria 32.1 IL13 IL2 IL2RA
2 poliomyelitis 31.2 IFNG IL10 IL4
3 measles 30.7 CD40LG IFNG IL2 IL4
4 rubella 30.7 CD40LG IL10 IL4
5 lepromatous leprosy 30.4 IFNG IL10 IL2
6 mumps 30.3 CD40LG IFNG IL2 IL2RA
7 reactive arthritis 30.2 CD79A IFNG IL10
8 hematopoietic stem cell transplantation 30.0 IFNG IL10 IL2
9 herpes zoster 30.0 IFNG IL10 IL2
10 erythema multiforme 29.9 CD79A IFNG IL2
11 onchocerciasis 29.9 IL13 IL2 IL4 IL5
12 wells syndrome 29.8 IL2 IL2RA IL5
13 milk allergy 29.8 CD79A IL10 IL4 IL5
14 myasthenia gravis 29.8 IFNG IL10 IL2 IL4
15 meningitis 29.7 CD40LG IFNG IL10
16 leprosy 3 29.7 CD40LG CD79A IFNG IL10 IL2 IL4
17 pneumonia 29.7 CD40LG IL10 IL13 IL5
18 cervicitis 29.7 CD79A IL2 IL2RA
19 rheumatic disease 29.5 CD40LG IFNG IL10 IL2RA
20 ige responsiveness, atopic 29.3 IFNG IL10 IL13 IL4 IL5
21 allergic hypersensitivity disease 29.3 IFNG IL10 IL13 IL4 IL5
22 rheumatoid arthritis 29.1 CD40LG CD79A IFNG IL10 IL2 IL4
23 psoriasis 29.0 IFNG IL10 IL13 IL2 IL2RA IL4
24 malaria 28.8 CD40LG IFNG IL10 IL13 IL2 IL4
25 systemic lupus erythematosus 28.6 CD40LG CD79A IFNG IL10 IL2 IL2RA
26 schistosomiasis 28.5 CD40LG CD79A IFNG IL10 IL13 IL2
27 multiple sclerosis 28.4 CCR7 IFNG IL10 IL2 IL2RA IL4
28 asthma 28.4 CD40LG CD79A IFNG IL10 IL13 IL2RA
29 tetanus neonatorum 12.5
30 cold-induced sweating syndrome 1 11.2
31 immunodeficiency 25 10.9
32 specific antibody deficiency 10.9
33 pertussis 10.7
34 mycoplasmal pneumonia 10.6 IFNG IL4
35 juvenile spondyloarthropathy 10.6 IL2 LTA
36 ross river fever 10.6 CD40LG IL10
37 tropical endomyocardial fibrosis 10.6 IL10 IL4
38 variola major 10.6 IFNG IL2
39 selective igg deficiency disease 10.5 CD40LG CD79A
40 neuroschistosomiasis 10.5 CD79A IFNG
41 c1q nephropathy 10.5 CD40LG CD79A
42 eosinophilic fasciitis 10.5 IFNG IL5
43 immune suppression 10.5 IFNG IL10 IL2
44 influenza 10.5
45 meningovascular neurosyphilis 10.5 CD40LG CD79A
46 alpha chain disease 10.5 CD40LG CD79A
47 brill-zinsser disease 10.5 CD40LG CD79A
48 exudative glomerulonephritis 10.5 CD40LG CD79A
49 chronic active epstein-barr virus infection 10.5 IFNG IL10 IL2
50 cork-handlers' disease 10.5 CD40LG CD79A

Graphical network of the top 20 diseases related to Tetanus:



Diseases related to Tetanus

Symptoms & Phenotypes for Tetanus

UMLS symptoms related to Tetanus:


pruritus, fever

GenomeRNAi Phenotypes related to Tetanus according to GeneCards Suite gene sharing:

25 (show all 45)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.19 IL10 CCR7
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.19 IL13
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.19 IL10
4 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.19 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.19 IL10 CCR7 IL13 VAMP7
6 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.19 IL13
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.19 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.19 VAMP7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.19 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.19 VAMP7
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.19 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.19 CCR7
13 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.19 IL10 CCR7
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.19 IL13
15 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.19 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.19 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.19 CCR7
18 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.19 VAMP7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.19 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.19 VAMP7
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.19 IL13
22 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.19 VAMP7
23 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.19 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.19 VAMP7
25 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.19 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.19 VAMP7
27 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.19 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.19 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.19 IL10
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.13 IL2RA
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.13 IL2RA
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.13 NSF IL10
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.13 IL2RA NSF IL10 VAMP7
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.13 IL2RA
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.13 VAMP7
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.13 VAMP7
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.13 IL2RA
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.13 NSF
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.13 IL2RA IL10
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.13 IL10
41 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.13 IL10
42 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.13 IL10
43 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.13 NSF
44 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 LTA STX3 CD40LG IL10 IL2 IL2RA
45 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 LTA STX3 CD27 CD40LG IL10 IL2

MGI Mouse Phenotypes related to Tetanus:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 VAMP3 VAMP7 IL13 CD79A IFNG IL2
2 hematopoietic system MP:0005397 10.3 VAMP2 VAMP3 CD79A IFNG IL2 CCR7
3 immune system MP:0005387 10.28 VAMP3 IFNG IL2 CCR7 IL10 CD27
4 endocrine/exocrine gland MP:0005379 10.22 VAMP2 IL13 IFNG IL2 CCR7 IL10
5 mortality/aging MP:0010768 10.13 VAMP2 IL13 IFNG IL10 CD40LG SNAP25
6 digestive/alimentary MP:0005381 10.1 IL13 IFNG CCR7 IL10 IL4 IL5
7 nervous system MP:0003631 10 VAMP2 VAMP3 VAMP7 CD79A IFNG CCR7
8 liver/biliary system MP:0005370 9.97 CD79A IFNG IL10 IL4 SNAP25 IL5
9 no phenotypic analysis MP:0003012 9.81 CD79A IL13 IFNG CCR7 IL10 IL4
10 respiratory system MP:0005388 9.61 IL13 IFNG IL10 IL4 SNAP25 IL5
11 vision/eye MP:0005391 9.28 IFNG CCR7 IL10 IL4 SNAP25 IL2

Drugs & Therapeutics for Tetanus

Drugs for Tetanus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 301)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
2
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
3
Remifentanil Approved Phase 4 132875-61-7 60815
4
Natalizumab Approved, Investigational Phase 4 189261-10-7
5
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
6
Methotrexate Approved Phase 4,Phase 2 1959-05-2, 59-05-2 126941
7
rituximab Approved Phase 4,Phase 2 174722-31-7 10201696
8
Adalimumab Approved Phase 4 331731-18-1 16219006
9
Etanercept Approved, Investigational Phase 4 185243-69-0
10
Desflurane Approved Phase 4 57041-67-5 42113
11
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
12
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
13
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
14
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
15
Daclizumab Approved, Investigational Phase 4,Phase 2 152923-56-3
16
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
17
Ibuprofen Approved Phase 4 15687-27-1 3672
18
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
19
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
20
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
21
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
22
Lopinavir Approved Phase 4 192725-17-0 92727
23
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
25
leucovorin Approved, Nutraceutical Phase 4,Phase 2 58-05-9 143 6006
26 tannic acid Approved, Nutraceutical Phase 4
27
BCG vaccine Investigational Phase 4,Phase 2
28 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
30 Antacids Phase 4,Phase 3,Phase 2,Phase 1
31 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1
34 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antidotes Phase 4,Phase 3,Phase 2
37 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Antirheumatic Agents Phase 4,Phase 1,Phase 2
39 Calcium, Dietary Phase 4,Phase 3,Phase 2
40 Antimetabolites Phase 4,Phase 2,Phase 1
41 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 1
42 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Vitamin B Complex Phase 4,Phase 2
44 Aluminum phosphate Phase 4,Phase 3,Phase 1,Phase 2
45 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
46 Analgesics, Opioid Phase 4
47 Anesthetics Phase 4,Phase 1
48 Anesthetics, General Phase 4
49 Anesthetics, Intravenous Phase 4
50 Central Nervous System Depressants Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 612)

# Name Status NCT ID Phase Drugs
1 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
2 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
3 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
4 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
5 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
6 Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td Completed NCT00601835 Phase 4
7 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
8 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
9 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
10 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Completed NCT00347958 Phase 4
11 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
12 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Completed NCT00457249 Phase 4
13 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
14 Study of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
15 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® Completed NCT00319553 Phase 4
16 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
17 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
18 Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids™ Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix™ (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
19 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
20 Post Marketing Surveillance for ADACEL™ in South Korea Completed NCT01137435 Phase 4
21 Tdap Vaccine in Post-Partum Women Completed NCT01711645 Phase 4
22 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
23 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
24 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
25 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
26 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
27 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
28 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
29 Interest of a Tetanus Test at a Fixed Remifentanil Concentration Before Laryngoscopy and Skin Incision Completed NCT02884310 Phase 4 Remifentanil adapted to SPI;Remifentanil fixed
30 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
31 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. Completed NCT00610168 Phase 4
32 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
33 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed NCT00777257 Phase 4
34 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
35 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
36 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
37 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
38 Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA) Completed NCT00111410 Phase 4 Anakinra (r-metHuIL-1ra)
39 Tropical Influenza Control Strategies for the Elderly Completed NCT02655874 Phase 4
40 Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients Completed NCT00287677 Phase 4 HAART
41 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
42 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
43 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination Completed NCT00548171 Phase 4
44 Immunology of Non-specific Effects of Vaccine Completed NCT00168545 Phase 4
45 Evaluation of Boostrix™10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
46 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
47 Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) Completed NCT01294605 Phase 4
48 Immunogenicity of the Booster Dose of Two MenC Vaccines Completed NCT00392808 Phase 4
49 A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA) Completed NCT01163747 Phase 4 methotrexate
50 Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Completed NCT00635128 Phase 4

Search NIH Clinical Center for Tetanus

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: tetanus

Genetic Tests for Tetanus

Anatomical Context for Tetanus

MalaCards organs/tissues related to Tetanus:

38
T Cells, Testes, Brain, Bone, Spinal Cord, Heart, Skeletal Muscle

Publications for Tetanus

Articles related to Tetanus:

(show top 50) (show all 1077)
# Title Authors Year
1
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults. ( 29172945 )
2018
2
Lichen planus following tetanus-diphtheria-acellular pertussis vaccination: A case report and review of the literature. ( 29326823 )
2018
3
Repeated vaccination with tetanus toxoid of plasma donors with pre-existing specific IgE transiently elevates tetanus-specific IgE but does not induce allergic symptoms. ( 29383792 )
2018
4
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. ( 29336924 )
2018
5
Sero-efficacy of Vi-polysaccharide tetanus-toxoid typhoid conjugate vaccine (Typbar-TCV). ( 29351594 )
2018
6
A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital. ( 29217370 )
2018
7
Immunogenicity and safety of a novel tetanus toxoid-conjugated anti-gastrin vaccine in BALB/c mice. ( 29306507 )
2018
8
Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. ( 29254840 )
2018
9
Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. ( 29438562 )
2018
10
Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. ( 29231748 )
2018
11
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. ( 29066131 )
2018
12
Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses. ( 28081174 )
2017
13
Tetanus Toxoid carrier protein induced T-helper cell responses upon vaccination of middle-aged adults. ( 28882444 )
2017
14
Knowledge, attitudes and practices related to tetanus toxoid vaccination in women of childbearing age: A cross-sectional study in peri-urban settlements of Karachi, Pakistan. ( 29317900 )
2017
15
Identification of a Tetanus Toxin Specific Epitope in Single Amino Acid Resolution. ( 28922578 )
2017
16
Tetanus: A Report of Two Cases and Review of Literature - A Continuing Threat to the Elderly in Japan. ( 29326519 )
2017
17
High Conservation of Tetanus and Botulinum Neurotoxins Cleavage Sites on Human SNARE Proteins Suggests That These Pathogens Exerted Little or No Evolutionary Pressure on Humans. ( 29257047 )
2017
18
Nanoporous Microneedle Arrays Effectively Induce Antibody Responses against Diphtheria and Tetanus Toxoid. ( 29375544 )
2017
19
Soil transmitted helminth infections are not associated with compromised antibody responses to previously administered measles and tetanus vaccines among HIV-1 infected, ART naA^ve Kenyan adults. ( 28924616 )
2017
20
Committee Opinion No. 718 Summary: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. ( 28832480 )
2017
21
Diagnostic Accuracy of Quick Stick for Identifying Traumatic Patients in Need of Tetanus Prophylaxis; a Cross-sectional Study. ( 28894781 )
2017
22
Committee Opinion No. 718: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. ( 28832489 )
2017
23
Co-administration of BCG and Diphtheria-tetanus-pertussis (DTP) Vaccinations May Reduce Infant Mortality More Than the WHO-schedule of BCG First and Then DTP. A Re-analysis of Demographic Surveillance Data From Rural Bangladesh. ( 28784413 )
2017
24
Tetanus, diphtheria, and acellular pertussis vaccination during pregnancy and reduced risk of infant acute respiratory infections. ( 28916245 )
2017
25
Sex-differential effects of diphtheria-tetanus-pertussis vaccine for the outcome of paediatric admissions? A hospital based observational study from Guinea-Bissau. ( 29107347 )
2017
26
Neuroprotective effects of C-terminal domain of tetanus toxin on rat brain against motorneuron damages after experimental spinal cord injury. ( 28767631 )
2017
27
Tetanus vaccination, antibody persistence and decennial booster; Reply to 'New guidelines about tetanus vaccination schedules in Europe should be evaluated with caution' by Eldin and co-workers. ( 28803553 )
2017
28
Long-term outcome in survivors of neonatal tetanus following specialist intensive care in Vietnam. ( 28946862 )
2017
29
Functionally Convergent B Cell Receptor Sequences in Transgenic Rats Expressing a Human B Cell Repertoire in Response to Tetanus Toxoid and Measles Antigens. ( 29312330 )
2017
30
Clinical Profile and Outcome of Pediatrics Tetanus: The Experience of a Tertiary Hospital in Ethiopia. ( 29217961 )
2017
31
Hib antibody responses in infants following diphtheria, tetanus, acellular pertussis, and conjugated Haemophilus influenzae type b (Hib) combination vaccines with decreasing amounts of tetanus toxoid. ( 29054729 )
2017
32
Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy. ( 29263885 )
2017
33
Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. ( 28965718 )
2017
34
Progress towards achieving and maintaining maternal and neonatal tetanus elimination in the African region. ( 29296159 )
2017
35
Non-protective immunity against tetanus in primiparous women and newborns at birth in rural and urban settings in Ibadan, Nigeria. ( 29296161 )
2017
36
Subcutaneous diphtheria and tetanus vaccines in children with haemophilia: A pilot study and review of the literature. ( 28780770 )
2017
37
Strategies to increase immunization coverage of tetanus vaccine among women in Sub Saharan Africa: a systematic review. ( 29296160 )
2017
38
Demand- and supply-side determinants of diphtheria-pertussis-tetanus nonvaccination and dropout in rural India. ( 28081971 )
2017
39
Negative Correlation between Circulating CD4(+)FOXP3(+)CD127(-) Regulatory T Cells and Subsequent Antibody Responses to Infant Measles Vaccine but Not Diphtheria-Tetanus-Pertussis Vaccine Implies a Regulatory Role. ( 28855899 )
2017
40
Tetanus-induced Trismus: Improvement on a Daily Basis. ( 28924130 )
2017
41
Tetanus attacks an old person with inadequate vaccination showing 'Risus Sardonicus' face. ( 28875124 )
2017
42
Diphtheria, pertussis, and tetanus: evidence-based management of pediatric patients in the emergency department ( 28749121 )
2017
43
Verification of Neonatal Tetanus Surveillance Systems in Katsina State, Nigeria. ( 28944276 )
2017
44
Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid. ( 27927058 )
2017
45
Diphtheria, pertussis, and tetanus: evidence-based management of pediatric patients in the emergency department [digest]. ( 28749625 )
2017
46
Letter to the Editor: New guidelines about tetanus vaccination schedules in Europe should be evaluated with caution; Comment on: Tetanus vaccination, antibody persistence and decennial booster: a serosurvey of university students and at-risk workers. By Borrella-Venturini et al. ( 28803561 )
2017
47
Clinical features and outcomes of tetanus: Analysis using a National Inpatient Database in Japan. ( 29304489 )
2017
48
Using the 4 Pillarsa8c Practice Transformation Program to increase adolescent human papillomavirus, meningococcal, tetanus-diphtheria-pertussis and influenza vaccination. ( 28947346 )
2017
49
Augmentation of humoral and cellular immunity in response to Tetanus and Diphtheria toxoids by supercritical carbon dioxide extracts of Hippophae rhamnoides L. leaves. ( 28092864 )
2017
50
A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex. ( 27171114 )
2016

Variations for Tetanus

Expression for Tetanus

Search GEO for disease gene expression data for Tetanus.

Pathways for Tetanus

Pathways related to Tetanus according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 CD27 CD40LG CD79A IFNG IL10 IL13
2
Show member pathways
13.85 CCR7 CD27 CD40LG IL10 IL13 IL2
3
Show member pathways
13.71 CCR7 CD27 CD40LG IFNG IL10 IL13
4
Show member pathways
13.55 IFNG IL10 IL13 IL2 IL2RA IL4
5
Show member pathways
13.47 CCR7 CD27 CD40LG IL10 IL13 IL2
6
Show member pathways
13.39 CD27 CD40LG IFNG IL10 IL13 IL2
7
Show member pathways
13.35 CCR7 CD27 CD40LG IL10 IL13 IL2
8
Show member pathways
12.9 CD40LG IFNG IL10 IL13 IL2 IL2RA
9 12.87 IFNG IL13 IL2 IL2RA IL4 IL5
10
Show member pathways
12.83 IFNG IL13 IL2 IL2RA IL4 LTA
11
Show member pathways
12.71 CD40LG CD79A IFNG IL10 IL2 IL2RA
12
Show member pathways
12.66 IFNG IL10 IL13 IL2 IL2RA IL4
13 12.62 CD40LG CD79A IFNG IL10 IL2 IL2RA
14
Show member pathways
12.52 CD40LG IFNG IL10 IL2 IL4 IL5
15
Show member pathways
12.48 NSF SNAP23 SNAP25 VAMP2 VAMP7
16
Show member pathways
12.4 IFNG IL10 IL13 IL2 IL2RA IL4
17
Show member pathways
12.34 IFNG IL13 IL4 IL5
18
Show member pathways
12.27 CD40LG IFNG IL10 IL4
19 12.2 IL10 IL13 SNAP25 VAMP2
20
Show member pathways
12.16 IFNG IL10 IL13 IL2 IL4 IL5
21
Show member pathways
12.06 IL13 IL2 IL2RA IL5
22
Show member pathways
12.03 NSF SNAP25 STX3 VAMP2
23
Show member pathways
12.01 IFNG IL2 IL2RA IL4
24
Show member pathways
12.01 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
25
Show member pathways
11.97 IFNG IL10 IL2 LTA
26 11.92 CCR7 CD79A IFNG IL10 IL2 IL2RA
27 11.89 IFNG IL10 IL2 IL2RA
28 11.88 IFNG IL13 IL2 IL4 IL5
29
Show member pathways
11.85 CCR7 IFNG IL4
30
Show member pathways
11.81 CD40LG IFNG IL2 IL2RA IL4 IL5
31
Show member pathways
11.8 CD27 CD40LG LTA
32
Show member pathways
11.77 IL2 IL2RA IL4 LTA
33 11.75 IFNG IL10 IL2
34 11.74 CD40LG IL10 IL4 IL5 LTA
35 11.73 CD40LG IL10 IL2RA IL4 IL5 LTA
36 11.68 IL13 IL4 IL5
37
Show member pathways
11.68 CD40LG IFNG IL2
38
Show member pathways
11.66 IFNG IL2 IL2RA
39 11.59 CD27 CD40LG IL10
40 11.55 IL10 IL13 IL4
41 11.55 CD40LG IFNG IL10
42
Show member pathways
11.47 IFNG IL10 IL2 IL2RA
43 11.46 IFNG IL10 IL13 IL2 IL2RA IL4
44
Show member pathways
11.44 NSF SNAP25 VAMP2
45 11.41 IFNG IL13 IL4 IL5
46 11.36 CD40LG IFNG IL2 IL2RA IL4 IL5
47 11.36 IFNG IL10 IL13 IL2 IL2RA IL4
48 11.34 IFNG IL13 IL2 IL2RA
49 11.28 IFNG IL10 IL13 IL2 IL4 IL5
50 11.27 CD40LG IL10 IL13 IL2 IL4 IL5

GO Terms for Tetanus

Cellular components related to Tetanus according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.97 CCR7 CD27 CD40LG IFNG IL2 IL2RA
2 synapse GO:0045202 9.96 SNAP23 SNAP25 VAMP2 VAMP3 VAMP7
3 cell surface GO:0009986 9.93 CCR7 CD27 CD40LG IL2RA VAMP3 VAMP7
4 phagocytic vesicle membrane GO:0030670 9.67 SNAP23 VAMP3 VAMP7
5 synaptic vesicle GO:0008021 9.67 SNAP25 STX3 VAMP2 VAMP7
6 clathrin-coated vesicle membrane GO:0030665 9.65 VAMP2 VAMP3 VAMP7
7 neuron projection GO:0043005 9.63 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
8 specific granule GO:0042581 9.57 SNAP23 STX3
9 secretory granule GO:0030141 9.56 STX3 VAMP2 VAMP3 VAMP7
10 azurophil granule GO:0042582 9.54 SNAP23 STX3
11 intracellular organelle GO:0043229 9.52 VAMP2 VAMP3
12 zymogen granule membrane GO:0042589 9.51 STX3 VAMP2
13 synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex GO:0070032 9.43 SNAP25 VAMP2
14 external side of plasma membrane GO:0009897 9.43 CCR7 CD27 CD40LG CD79A IL13 IL2RA
15 SNARE complex GO:0031201 9.1 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
16 plasma membrane GO:0005886 10.25 CCR7 CD27 CD40LG CD79A IL2RA LTA
17 extracellular region GO:0005576 10.23 CD27 CD40LG IFNG IL10 IL13 IL2
18 extracellular space GO:0005615 10.15 CD40LG IFNG IL10 IL13 IL2 IL4

Biological processes related to Tetanus according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.97 CCR7 CD27 IL10 IL13 LTA
2 B cell differentiation GO:0030183 9.87 CD40LG CD79A IL10 IL4
3 inflammatory response GO:0006954 9.87 CCR7 CD27 CD40LG IL10 IL13 IL2RA
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IFNG IL13 IL2
5 positive regulation of T cell proliferation GO:0042102 9.84 CD40LG IL2 IL2RA IL4
6 vesicle fusion GO:0006906 9.83 STX3 VAMP2 VAMP3 VAMP7
7 exocytosis GO:0006887 9.8 NSF STX3 VAMP2 VAMP3 VAMP7
8 B cell proliferation GO:0042100 9.79 CD40LG CD79A IL10
9 negative regulation of endothelial cell apoptotic process GO:2000352 9.79 IL10 IL13 IL4
10 Golgi to plasma membrane protein transport GO:0043001 9.78 VAMP2 VAMP3 VAMP7
11 long-term synaptic potentiation GO:0060291 9.78 MPP2 SNAP25 STX3 VAMP2
12 positive regulation of interleukin-12 production GO:0032735 9.77 CCR7 CD40LG IFNG
13 post-Golgi vesicle-mediated transport GO:0006892 9.76 SNAP23 VAMP2 VAMP7
14 regulation of receptor activity GO:0010469 9.76 CD40LG IFNG IL10 IL13 IL2 IL4
15 regulation of regulatory T cell differentiation GO:0045589 9.73 IFNG IL2 IL2RA
16 positive regulation of B cell proliferation GO:0030890 9.73 IL13 IL2 IL4 IL5
17 calcium ion regulated exocytosis GO:0017156 9.72 VAMP2 VAMP3 VAMP7
18 synaptic vesicle fusion to presynaptic active zone membrane GO:0031629 9.69 SNAP23 SNAP25 STX3
19 synaptic vesicle priming GO:0016082 9.68 SNAP23 SNAP25
20 positive regulation of isotype switching to IgG isotypes GO:0048304 9.67 IL2 IL4
21 synaptic vesicle docking GO:0016081 9.67 SNAP25 STX3
22 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL2 IL5 VAMP3
23 membrane fusion GO:0061025 9.67 SNAP23 STX3 VAMP2 VAMP3
24 positive regulation of MHC class II biosynthetic process GO:0045348 9.66 IL10 IL4
25 negative regulation of lymphocyte proliferation GO:0050672 9.66 IL2 IL2RA
26 type 2 immune response GO:0042092 9.65 IL10 IL4
27 natural killer cell degranulation GO:0043320 9.65 VAMP2 VAMP7
28 mucus secretion GO:0070254 9.65 VAMP2 VAMP3
29 regulation of isotype switching GO:0045191 9.64 IL10 IL4
30 eosinophil degranulation GO:0043308 9.64 VAMP2 VAMP7
31 regulation of T cell homeostatic proliferation GO:0046013 9.63 IL2 IL2RA
32 regulation of histamine secretion by mast cell GO:1903593 9.63 VAMP2 VAMP3
33 SNARE complex assembly GO:0035493 9.63 VAMP2 VAMP3 VAMP7
34 negative regulation of complement-dependent cytotoxicity GO:1903660 9.62 IL13 IL4
35 exocytic insertion of neurotransmitter receptor to postsynaptic membrane GO:0098967 9.43 SNAP25 STX3 VAMP2
36 immune response GO:0006955 9.36 CCR7 CD27 CD40LG IFNG IL10 IL13
37 positive regulation of T cell differentiation GO:0045582 9.26 CD27 IL2 IL2RA IL4
38 negative regulation of apoptotic process GO:0043066 10.08 CD27 CD40LG IL10 IL2 IL4
39 vesicle-mediated transport GO:0016192 10 NSF STX3 VAMP2 VAMP3 VAMP7

Molecular functions related to Tetanus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.71 IL10 IL2 IL4 IL5
2 syntaxin binding GO:0019905 9.62 NSF SNAP23 VAMP2 VAMP7
3 syntaxin-1 binding GO:0017075 9.56 NSF SNAP25 VAMP2 VAMP3
4 cytokine activity GO:0005125 9.56 CD40LG IFNG IL10 IL13 IL2 IL4
5 SNARE binding GO:0000149 9.55 NSF STX3 VAMP2 VAMP3 VAMP7
6 SNAP receptor activity GO:0005484 9.1 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
7 protein binding GO:0005515 10.32 CD27 CD40LG CD79A IFNG IL10 IL13

Sources for Tetanus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....